drugset / Trial / NCT01471717

Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects

NCT01471717

Phase 1/2 Completed 32 enrolled Bristol-Myers Squibb
RandomizedFactorialQuadruple-blindHealth-services research

Summary

This study is designed to evaluate the potential for a pharmacokinetic drug-drug interaction between INX-08189 and Victrelis, a Direct Acting Antiviral (DAA).

Timeline

Start
2011-10
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986094 Small molecule 50 mg
Comparator Boceprevir Small molecule 800 mg

Indications

No indication recorded.